The Triple Test, also known as the Triple Marker test, is a screening performed during the second trimester of pregnancy to assess the risk of chromosomal abnormalities and neural tube defects in the baby. This test helps classify a patient as either high-risk or low-risk for conditions such as Down syndrome (Trisomy 21), Trisomy 18, and spina bifida. It provides valuable information about the likelihood of the baby being affected by these conditions, aiding in decision-making for further diagnostic testing if necessary.